Emyria Limited’s (ASX: EMD) newly inaugurated Empax Centre has been selected as a key site for a clinical trial sponsored by New York-based Transcend Therapeutics.
The trial will evaluate the safety and efficacy of methylone, a novel rapid-acting neuroplastogen known for promoting new nerve cell growth in areas affected by PTSD, depression, and anxiety.
Emyria’s Empax Centre is a state-of-the-art facility dedicated to the delivery and evaluation of new treatments for mental health. It provides critical infrastructure for the safe administration and evaluation of new medications in both clinical trial and Real-World settings and embodies Emyria’s mission to deliver and develop new treatments that significantly improve patient outcomes.
Emyria will receive compensation for facilitating the trial, highlighting its value and expertise in psychological trauma care and clinical trial delivery. This recognition underscores Emyria’s leadership in mental health innovation.
“We are delighted to work with Transcend Therapeutics on this exciting trial that highlights our dedication to bringing new treatments to our patients while utilising the full capabilities of our Empax Centre,” CEO, Dr. Michael Winlo, said.
“Site selection is international recognition of our team’s unique capabilities and we look forward to working with Transcend Therapeutics and our network of specialists to advance this trial and improve mental health outcomes for patients with severe PTSD.”
